Prospective Cohort Study to Determine Effectiveness of Telemedicine-based on Site Hepatitis C Management in Probation and Parole Office
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Hepatitis C
- Sponsor
- Jens Rosenau
- Enrollment
- 77
- Locations
- 1
- Primary Endpoint
- HCV treatment uptake rate of HCV RNA positive participants
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This prospective cohort study compares aims to determine the efficacy and effectiveness of telemedicine-supported on-site linkage to care and treatment in a community probation and parole office (P&P office) setting and compare the results with a historic control with referral to care. Research participants will be followed in the P&P office when they report to their officer during regularly scheduled appointments. Participants will receive treatment without having to travel to a specialist's office. The telemedicine visit will include a consultation with an experienced HCV provider such as a hepatologist or an advanced practice provider and a specialty pharmacist who will educate about and monitor HCV treatment. The UK specialty pharmacy will be available to participants and the HCV management team through a 24-hour support line. Participants will be treated per HCV guidelines and insurance preference.
Investigators
Jens Rosenau
Associate Professor
University of Kentucky
Eligibility Criteria
Inclusion Criteria
- •Clients who will be supervised in the probation and parole office for at least 5 months
- •History of hepatitis C
- •Able to obtain health insurance
- •Capacity to provide written, informed consent
- •Life expectancy \>1 year
Exclusion Criteria
- •Negative HCV RNA
- •Pregnant or breast-feeding
- •HIV or HBV co-infection
- •Liver cirrhosis with Child-Turcotte-Pugh score 6 or greater at baseline lab work
- •Subjects with impaired capacity to provide informed consent
Outcomes
Primary Outcomes
HCV treatment uptake rate of HCV RNA positive participants
Time Frame: 6 months
Percentage of treatment uptake among treatment eligible patients seen by a provider via telemedicine.
Secondary Outcomes
- HCV treatment uptake rate(6 months)
- Determine visit adherence(6 months)